CD276 Recombinant Proteins
CD276, also known as B7-H3, is an immune checkpoint protein belonging to the B7 family of costimulatory molecules. It is involved in modulating T-cell-mediated immune responses and is overexpressed in various cancers. CD276 recombinant proteins are engineered to mimic the native structure and function of the CD276 protein, facilitating research into its role in immune regulation, cancer immunotherapy, and cell signaling.
Content on CD276 Recombinant Proteins
CD276 recombinant proteins are produced using advanced expression systems, such as mammalian cells or E. coli, to ensure proper folding and post-translational modifications. These proteins exhibit high purity and functionality, retaining their immunoregulatory characteristics. Key features of CD276 recombinant proteins include:
- Molecular Structure: Typically provided as full-length or extracellular domain forms.
- Expression: Often expressed in HEK293 or CHO cells for optimal glycosylation and bioactivity.
- Purity: >95% purity, as verified by SDS-PAGE and HPLC.
Application of CD276 Recombinant Proteins
- Cancer Immunotherapy Research:
- Used to study CD276-mediated immune evasion mechanisms in cancer.
- Evaluated as a target for antibody-based therapies and immune checkpoint inhibitors.
- Functional Assays:
- Applied in co-culture assays to investigate T-cell activation and suppression.
- Used in ligand-receptor interaction studies.
- Antibody Development:
- Supports the generation and validation of monoclonal and polyclonal antibodies targeting CD276.
- Diagnostics:
- Serves as a control or standard in diagnostic assays for detecting CD276 expression levels in tumor samples.
CD276 recombinant proteins provide a robust platform for understanding the immunological and oncological significance of the B7-H3 molecule. Their high-quality production and functional relevance make them indispensable tools in cancer immunotherapy research, biomarker discovery, and therapeutic development.
|
|
|
|
|
|
|
|
|
|
|
|
|
|